Search Results - "Adalimumab"

Efficacy of Adalimumab Biosimilars in Managing Perianal Fistula in Moderate to Severe Crohn's Disease: A Systematic Review and Meta-Analysis.

Authors: Abdelrehim KMM Elganyni AKE Elagouz AEE et al.

Source: La Clinica terapeutica [Clin Ter] 2025 Nov-Dec; Vol. 176 (6), pp. 839-845.

Publication Type: Journal Article; Systematic Review; Meta-Analysis

Journal Info: Publisher: Societa Editrice Universo Country of Publication: Italy NLM ID: 0372604 Publication Model: Print Cited Medium: Internet ISSN: 1972-6007 (Electronic) Linking ISSN: 00099074 NLM ISO Abbreviation: Clin Ter Subsets: MEDLINE

MeSH Terms: Adalimumab*/therapeutic use , Adalimumab*/adverse effects , Crohn Disease*/complications , Biosimilar Pharmaceuticals*/therapeutic use , Biosimilar Pharmaceuticals*/adverse effects , Rectal Fistula*/drug therapy , Rectal Fistula*/etiology, Humans ; Severity of Illness Index ; Treatment Outcome ; Randomized Controlled Trials as Topic

Bortezomib for the treatment of anti-N-methyl-d-aspartate receptor encephalitis in a patient with psoriatic arthritis receiving adalimumab: A case report and literature review.

Authors: Karigowda L Brown D Wong C et al.

Source: Journal of neuroimmunology [J Neuroimmunol] 2025 Dec 15; Vol. 409, pp. 578754. Date of Electronic Publication: 2025 Sep 09.

Publication Type: Journal Article; Case Reports; Review

Journal Info: Publisher: Elsevier/North-Holland Country of Publication: Netherlands NLM ID: 8109498 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8421 (Electronic) Linking ISSN: 01655728 NLM ISO Abbreviation: J Neuroimmunol Subsets: MEDLINE

MeSH Terms: Anti-N-Methyl-D-Aspartate Receptor Encephalitis*/drug therapy , Anti-N-Methyl-D-Aspartate Receptor Encephalitis*/chemically induced , Bortezomib*/therapeutic use , Adalimumab*/adverse effects , Adalimumab*/therapeutic use , Arthritis, Psoriatic*/drug therapy , Arthritis, Psoriatic*/complications , Antirheumatic Agents*/adverse effects , Antirheumatic Agents*/therapeutic use , Proteasome Inhibitors*/therapeutic use, Humans ; Male ; Adult

Muscle Structure and Function Recovery: Adalimumab-Calcium Channel Synergy in Post-Ischemic Stroke Sarcopenia.

Authors: Qi H Zhang XW Zhang ZY et al.

Source: Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2025 Dec; Vol. 16 (6), pp. e70097.

Publication Type: Journal Article

Journal Info: Publisher: John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Country of Publication: Germany NLM ID: 101552883 Publication Model: Print Cited Medium: Internet ISSN: 2190-6009 (Electronic) Linking ISSN: 21905991 NLM ISO Abbreviation: J Cachexia Sarcopenia Muscle Subsets: MEDLINE

MeSH Terms: Sarcopenia*/drug therapy , Sarcopenia*/etiology , Sarcopenia*/pathology , Adalimumab*/pharmacology , Adalimumab*/therapeutic use , Calcium Channels*/metabolism , Ischemic Stroke*/complications , Ischemic Stroke*/drug therapy , Muscle, Skeletal*/drug effects , Muscle, Skeletal*/pathology, Animals ; Rats ; Male ; Disease Models, Animal ; Recovery of Function/drug effects ; Muscle Strength/drug effects

Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn's disease.

Authors: Carlsen A Steinsbø Ø Kvaløy JT et al.

Source: Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2025 Dec; Vol. 60 (12), pp. 1214-1225. Date of Electronic Publication: 2025 Oct 17.

Publication Type: Journal Article

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 0060105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1502-7708 (Electronic) Linking ISSN: 00365521 NLM ISO Abbreviation: Scand J Gastroenterol Subsets: MEDLINE

MeSH Terms: Adalimumab*/blood , Adalimumab*/therapeutic use , Adalimumab*/administration & dosage , Crohn Disease*/drug therapy , Crohn Disease*/blood , Drug Monitoring*/methods , Anti-Inflammatory Agents*/blood , Anti-Inflammatory Agents*/therapeutic use, Humans ; Female ; Male ; Adult ; C-Reactive Protein/analysis ; C-Reactive Protein/metabolism ; Cross-Sectional Studies ; Leukocyte L1 Antigen Complex/analysis ; Biomarkers/blood ; Longitudinal Studies ; Middle Aged ; Feces/chemistry ; Severity of Illness Index ; Young Adult ; Maintenance Chemotherapy

Effects of Immunomodulatory Therapy on the Skin Barrier Function in Patients with Psoriasis Vulgaris.

Authors: Mālkalne A Bondare-Ansberga V Hartmane I et al.

Source: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2025 Nov 20; Vol. 61 (11). Date of Electronic Publication: 2025 Nov 20.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE

MeSH Terms: Psoriasis*/drug therapy , Psoriasis*/physiopathology , Adalimumab*/therapeutic use , Adalimumab*/pharmacology , Skin*/drug effects , Skin*/physiopathology, Humans ; Adult ; Middle Aged ; Female ; Male ; Prospective Studies ; Severity of Illness Index ; Quality of Life ; Hydrogen-Ion Concentration ; Water Loss, Insensible/drug effects

Multiple eruptive dermatofibromas occurred after receiving sequential treatment with secukinumab, guselkumab, and adalimumab: case report.

Authors: Chen W Fang L Zhou Y

Source: Frontiers in immunology [Front Immunol] 2025 Nov 07; Vol. 16, pp. 1611831. Date of Electronic Publication: 2025 Nov 07 (Print Publication: 2025).

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Adalimumab*/adverse effects , Adalimumab*/administration & dosage , Psoriasis*/drug therapy , Histiocytoma, Benign Fibrous*/chemically induced , Histiocytoma, Benign Fibrous*/diagnosis , Histiocytoma, Benign Fibrous*/pathology , Skin Neoplasms*/chemically induced , Skin Neoplasms*/diagnosis , Skin Neoplasms*/pathology, Humans ; Male ; Adult

Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort.

Authors: Wang Y Gao J Li F et al.

Source: The Journal of dermatology [J Dermatol] 2025 Oct; Vol. 52 (10), pp. 1527-1535. Date of Electronic Publication: 2025 Aug 17.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7600545 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1346-8138 (Electronic) Linking ISSN: 03852407 NLM ISO Abbreviation: J Dermatol Subsets: MEDLINE

MeSH Terms: Arthritis, Psoriatic*/drug therapy , Arthritis, Psoriatic*/diagnosis , Adalimumab*/adverse effects , Adalimumab*/therapeutic use , Adalimumab*/administration & dosage , Heterocyclic Compounds, 3-Ring*/adverse effects , Heterocyclic Compounds, 3-Ring*/therapeutic use , Heterocyclic Compounds, 3-Ring*/administration & dosage , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/therapeutic use , Antirheumatic Agents*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Adult ; Treatment Outcome ; Severity of Illness Index ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects

Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic Diseases.

Authors: Golhen K Welzel T Atkinson A et al.

Source: Journal of clinical pharmacology [J Clin Pharmacol] 2025 Oct; Vol. 65 (10), pp. 1234-1245. Date of Electronic Publication: 2025 May 23.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

MeSH Terms: Adalimumab*/pharmacokinetics , Adalimumab*/administration & dosage , Adalimumab*/therapeutic use , Antirheumatic Agents*/pharmacokinetics , Antirheumatic Agents*/administration & dosage , Antirheumatic Agents*/therapeutic use , Antirheumatic Agents*/blood , Arthritis, Juvenile*/drug therapy , Rheumatic Diseases*/drug therapy, Humans ; Child ; Female ; Male ; Methotrexate/administration & dosage ; Methotrexate/therapeutic use ; Prospective Studies ; Adolescent ; Child, Preschool ; Models, Biological

Serum Anti-Drug Antibodies in Psoriasis Patients Undergoing Biologic Therapy in Real-World Clinical Practice: A Single-Center Retrospective Study.

Authors: Nozaki H Honma M Kishibe M et al.

Source: The Journal of dermatology [J Dermatol] 2025 Oct; Vol. 52 (10), pp. 1598-1602. Date of Electronic Publication: 2025 Aug 06.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7600545 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1346-8138 (Electronic) Linking ISSN: 03852407 NLM ISO Abbreviation: J Dermatol Subsets: MEDLINE

MeSH Terms: Psoriasis*/drug therapy , Psoriasis*/immunology , Psoriasis*/blood , Adalimumab*/immunology , Adalimumab*/therapeutic use , Antibodies, Monoclonal, Humanized*/immunology , Antibodies, Monoclonal, Humanized*/therapeutic use , Biological Products*/therapeutic use , Biological Products*/immunology, Humans ; Retrospective Studies ; Female ; Male ; Middle Aged ; Adult ; Aged ; Treatment Failure

Anti-TNFα therapy and microvascular changes: a case-based review of the potential association with early scleroderma pattern development.

Authors: Nigro A; Rheumatology Department of Lucania - UOSD of Rheumatology, 'Madonna delle Grazie' Hospital, Matera, Italy. Electronic address: angelonigro13@gmail.com.

Source: International immunopharmacology [Int Immunopharmacol] 2025 Dec 03; Vol. 166, pp. 115551. Date of Electronic Publication: 2025 Sep 19.

Publication Type: Journal Article; Case Reports; Review

Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

MeSH Terms: Tumor Necrosis Factor-alpha*/antagonists & inhibitors , Scleroderma, Systemic*/chemically induced , Scleroderma, Systemic*/diagnosis , Arthritis, Psoriatic*/drug therapy , Adalimumab*/adverse effects , Adalimumab*/therapeutic use , Antirheumatic Agents*/adverse effects , Antirheumatic Agents*/therapeutic use , Microvessels*/drug effects , Microvessels*/pathology, Humans ; Male ; Adult ; Microscopic Angioscopy

NMR-based structural integrity analysis of therapeutic monoclonal antibodies: a comparative study of Humira and its biosimilars.

Authors: Baldisseri D Luo S Ancajas CAF et al.

Source: MAbs [MAbs] 2025 Dec; Vol. 17 (1), pp. 2551208. Date of Electronic Publication: 2025 Sep 08.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE

MeSH Terms: Biosimilar Pharmaceuticals*/chemistry , Adalimumab*/chemistry, Magnetic Resonance Spectroscopy/methods ; Humans

Tumour necrosis factor inhibitors in Ulcerative colitis: real-world data on Therapeutic drug monitoring and evaluation of current treatment targets (STRIDE II).

Authors: Lundekvam JA Høivik ML Anisdahl K et al.

Source: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2424447. Date of Electronic Publication: 2025 Jan 06.

Publication Type: Journal Article

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH Terms: Colitis, Ulcerative*/drug therapy , Colitis, Ulcerative*/blood , Drug Monitoring*/methods , Adalimumab*/therapeutic use , Adalimumab*/administration & dosage , Adalimumab*/blood , Infliximab*/therapeutic use , Infliximab*/pharmacokinetics , Infliximab*/administration & dosage, Humans ; Male ; Female ; Adult ; Middle Aged ; Remission Induction/methods ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor Inhibitors/administration & dosage ; Retrospective Studies ; Gastrointestinal Agents/therapeutic use ; Gastrointestinal Agents/blood ; Gastrointestinal Agents/administration & dosage

Implementation of inline Raman spectroscopy for buffer exchange monitoring in monoclonal antibody formulation.

Authors: Vaskó D Hajdú DK Márkus E et al.

Source: International journal of pharmaceutics [Int J Pharm] 2025 Nov 10; Vol. 684, pp. 126129. Date of Electronic Publication: 2025 Sep 04.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE

MeSH Terms: Spectrum Analysis, Raman*/methods , Excipients*/chemistry , Antibodies, Monoclonal*/chemistry , Adalimumab*/chemistry, Buffers ; Chemistry, Pharmaceutical/methods ; Least-Squares Analysis ; 2-Hydroxypropyl-beta-cyclodextrin/chemistry ; Mannitol/chemistry ; Histidine/chemistry ; Sucrose/chemistry ; Calibration ; Drug Compounding/methods ; Technology, Pharmaceutical/methods

Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease.

Authors: Nice R Lin S Chanchlani N et al.

Source: The journal of applied laboratory medicine [J Appl Lab Med] 2025 Nov 04; Vol. 10 (6), pp. 1580-1592.

Publication Type: Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101693884 Publication Model: Print Cited Medium: Print ISSN: 2576-9456 (Print) Linking ISSN: 24757241 NLM ISO Abbreviation: J Appl Lab Med Subsets: MEDLINE

MeSH Terms: Crohn Disease*/drug therapy , Crohn Disease*/immunology , Crohn Disease*/blood , Adalimumab*/immunology , Adalimumab*/therapeutic use , Infliximab*/immunology , Infliximab*/therapeutic use , Tumor Necrosis Factor-alpha*/antagonists & inhibitors , Tumor Necrosis Factor-alpha*/immunology , Antibodies, Neutralizing*/blood , Antibodies, Neutralizing*/immunology , Tumor Necrosis Factor Inhibitors*/therapeutic use , Tumor Necrosis Factor Inhibitors*/immunology, Humans ; Male ; Female ; Adult ; Treatment Failure ; Cross Reactions/immunology ; Middle Aged

Adalimumab in refractory pediatric tubulointerstitial nephritis and uveitis syndrome: a case report of sustained renal-ocular remission and literature review.

Authors: Yang D Xi W Liu W et al.

Source: BMC nephrology [BMC Nephrol] 2025 Nov 03; Vol. 26 (1), pp. 609. Date of Electronic Publication: 2025 Nov 03.

Publication Type: Journal Article; Case Reports; Review

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369 (Electronic) Linking ISSN: 14712369 NLM ISO Abbreviation: BMC Nephrol Subsets: MEDLINE

MeSH Terms: Nephritis, Interstitial*/drug therapy , Nephritis, Interstitial*/diagnosis , Nephritis, Interstitial*/complications , Adalimumab*/therapeutic use , Uveitis*/drug therapy , Uveitis*/diagnosis , Uveitis*/complications , Anti-Inflammatory Agents*/therapeutic use, Humans ; Child ; Male ; Remission Induction/methods ; Treatment Outcome

SCR Disease Name: Tubulointerstitial nephritis and uveitis

Pediatric Patient With Generalized Pustular Psoriasis With MEFV Gene Variant: Successful Treatment With Adalimumab.

Authors: Kirwin DS Frantz T Nolan CF et al.

Source: Pediatric dermatology [Pediatr Dermatol] 2025 Nov-Dec; Vol. 42 (6), pp. 1206-1209. Date of Electronic Publication: 2025 Apr 14.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 8406799 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1470 (Electronic) Linking ISSN: 07368046 NLM ISO Abbreviation: Pediatr Dermatol Subsets: MEDLINE

MeSH Terms: Adalimumab*/therapeutic use , Psoriasis*/drug therapy , Psoriasis*/genetics , Pyrin*/genetics , Anti-Inflammatory Agents*/therapeutic use, Humans ; Child ; Male ; Female ; Treatment Outcome

Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis.

Authors: Wafae BGO Charrow AP Stein D et al.

Source: JAMA dermatology [JAMA Dermatol] 2025 Nov 01; Vol. 161 (11), pp. 1116-1122.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE

MeSH Terms: Adalimumab*/adverse effects , Adalimumab*/administration & dosage , Adalimumab*/therapeutic use , Psoriasis*/drug therapy , Hidradenitis Suppurativa*/drug therapy , Hidradenitis Suppurativa*/complications , Infections*/epidemiology , Infections*/etiology, Humans ; Female ; Male ; Adult ; Retrospective Studies ; Middle Aged ; Hospitalization/statistics & numerical data ; Length of Stay/statistics & numerical data ; Incidence

A CASE OF ACUTE ZONAL OCCULT OUTER RETINOPATHY UNDER IMMUNOMODULATORY TREATMENT.

Authors: Merle DA Wolfram L Nasyrov E et al.

Source: Retinal cases & brief reports [Retin Cases Brief Rep] 2025 Nov 01; Vol. 19 (6), pp. 793-798.

Publication Type: Journal Article; Case Reports

Journal Info: Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101298744 Publication Model: Print Cited Medium: Internet ISSN: 1937-1578 (Electronic) Linking ISSN: 19351089 NLM ISO Abbreviation: Retin Cases Brief Rep Subsets: MEDLINE

MeSH Terms: White Dot Syndromes*/drug therapy , White Dot Syndromes*/diagnosis , Scotoma*/drug therapy , Scotoma*/diagnosis , Prednisolone*/therapeutic use , Adalimumab*/therapeutic use, Humans ; Female ; Adult ; Glucocorticoids/therapeutic use ; Visual Fields

SCR Disease Name: Acute zonal occult outer retinopathy

Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab.

Authors: Granot M Nachum N Krauthammer A et al.

Source: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2025 Nov; Vol. 57 (11), pp. 2128-2134. Date of Electronic Publication: 2025 Sep 08.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 100958385 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3562 (Electronic) Linking ISSN: 15908658 NLM ISO Abbreviation: Dig Liver Dis Subsets: MEDLINE

MeSH Terms: Infliximab*/immunology , Infliximab*/therapeutic use , Infliximab*/administration & dosage , Adalimumab*/therapeutic use , Adalimumab*/immunology , Adalimumab*/administration & dosage , Drug Substitution* , Crohn Disease*/drug therapy , Crohn Disease*/immunology , Gastrointestinal Agents*/immunology , Gastrointestinal Agents*/therapeutic use , Colitis, Ulcerative*/drug therapy , Colitis, Ulcerative*/immunology , Inflammatory Bowel Diseases*/drug therapy , Inflammatory Bowel Diseases*/immunology, Humans ; Female ; Male ; Retrospective Studies ; Child ; Adolescent ; Treatment Outcome ; Antibodies/blood

Modulation of Nuclear Factor Kappa B Signaling and microRNA Profiles by Adalimumab in LPS-Stimulated Keratinocytes.

Authors: Plata-Babula A Kulej W Ordon P et al.

Source: International journal of molecular sciences [Int J Mol Sci] 2025 Oct 15; Vol. 26 (20). Date of Electronic Publication: 2025 Oct 15.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

MeSH Terms: Adalimumab*/pharmacology , Keratinocytes*/metabolism , Keratinocytes*/drug effects , MicroRNAs*/genetics , MicroRNAs*/metabolism , Lipopolysaccharides*/pharmacology , NF-kappa B*/metabolism , NF-kappa B*/genetics , Signal Transduction*/drug effects, Humans ; Gene Expression Profiling ; Gene Expression Regulation/drug effects ; HaCaT Cells ; Psoriasis/drug therapy ; Psoriasis/metabolism ; Psoriasis/genetics ; Tumor Necrosis Factor-alpha ; Anti-Inflammatory Agents/pharmacology ; Cell Line